Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound fulvate drug for silkworms

A technology of fulvic acid and silkworm medicine, applied in the field of sericulture, can solve the problems of unsuitability for simplified silkworm breeding, short duration of drug effect, corrosion of metal products, etc. Drug resistance, income-boosting effects

Active Publication Date: 2015-03-04
KUNMING UNIV OF SCI & TECH
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In actual production, chlorine preparations are mostly used for the prevention and treatment of viral diseases and protozoan diseases, but they have certain sensitization. At the same time, most chlorine preparations have a corrosive effect on cotton products and metal products; Use erythromycin, etc., but its properties are unstable, and the pathogenic bacteria of silkworms have developed a certain resistance to it; while the prevention and treatment of fungal diseases mostly use formaldehyde preparations, but it is harmful to the human body, and the drug effect lasts The time is short, the effect is not ideal
In addition, at present, the control of various diseases of silkworm is mainly based on single application of pesticides, which is relatively high in cost and complicated in operation, and does not meet the requirements of simplified silkworm rearing. Therefore, it is necessary to develop a new type of silkworm On the basis of satisfying the effective and comprehensive control of silkworm disease, it also has the characteristics of no toxic side effects and no drug resistance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound fulvate drug for silkworms
  • Compound fulvate drug for silkworms
  • Compound fulvate drug for silkworms

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] The compound silkworm medicine of fulvic acid salt described in this example is made from the following raw materials, and the raw materials and weight percentages are: 90% sodium fulvic acid, 9.69% degradation product of montan wax resin, 0.1% tea polyphenols of Puer tea, chitosan oligosaccharide 0.1%, Fucoidan sulfate 0.1%, Rhodiola rosea extract 0.004%, Bamboo leaf flavonoids 0.003%, Fangji extract 0.003%.

[0028] The preparation method of the compound silkworm medicine of fulvic acid salt described in the present embodiment is:

[0029] Firstly, the raw materials of the above-mentioned components after passing through an 80-mesh sieve were obtained respectively, and then 90 kg of sodium fulvic acid, 9.69 kg of montan wax resin degradation products, 0.1 kg of Pu’er tea polyphenols, 0.1 kg of chitosan oligosaccharides, and fucoidan sulfuric acid were prepared according to the weight ratio. Put 0.1 kg of ester, 0.004 kg of Rhodiola rosea extract, 0.003 kg of bamboo le...

Embodiment 2

[0058] The fulvic acid salt compound silkworm medicine composition and percentage by weight of the present embodiment are: potassium fulvic acid 88.98%, montan wax resin degradation product 8%, Pu'er tea polyphenols 1%, chitosan oligosaccharide 1%, fucoidan sulfuric acid Ester 1%, Rhodiola Rosea Extract 0.01%, Bamboo Leaf Flavonoids 0.005%, Fangji Extract 0.005%.

[0059] The preparation method of the compound silkworm medicine of fulvic acid salt described in the present embodiment is:

[0060] First of all, the raw materials of the above-mentioned components after passing through a 100-mesh sieve were obtained respectively, and then 88.98 kg of potassium fulvic acid, 8 kg of degraded montan wax resin, 1 kg of Pu’er tea polyphenols, 1 kg of chitosan oligosaccharide, and 1 kg of fucoidan sulfate were prepared according to the weight ratio. Put 1 kg of ester, 0.01 kg of Rhodiola rosea extract, 0.005 kg of bamboo leaf flavonoids, and 0.005 kg of Fangji extract into the mixing ke...

Embodiment 3

[0088] The fulvic acid salt compound silkworm medicine composition and weight percent of the present embodiment are: 45% sodium fulvic acid, 40% potassium fulvic acid, 13% degraded product of montan wax resin, 0.7% tea polyphenols of Puer tea, shell oligosaccharides Sugar 0.7%, Fucoidan sulfate 0.585%, Rhodiola rosea extract 0.007%, Bamboo leaf flavonoids 0.004%, Fangji extract 0.004%.

[0089] The preparation method of the compound silkworm medicine of fulvic acid salt described in the present embodiment is:

[0090] Firstly, the raw materials of the above-mentioned components after passing through a 90-mesh sieve are obtained respectively, and then according to the weight ratio, 45kg of sodium fulvate, 40kg of potassium fulvate, 13kg of degraded montan wax resin, 0.7kg of Pu'er tea polyphenols, and 0.7kg of chitosan oligosaccharides. kg, 0.585 kg of fucoidan sulfate, 0.007 kg of Rhodiola rosea extract, 0.004 kg of bamboo leaf flavonoids, and 0.004 kg of Fangji extract were p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound fulvate drug for silkworms, belonging to the technical field of silkworm cultivation. The compound fulvate drug for silkworms comprises the following components in percentage by weight: 85%-90% of fulvate, 8%-13% of lignite wax resin degradation products, 0.1%-1% of Pu'er tea polyphenol, 0.1%-1% of chitosan oligosaccharide, 0.1%-1% of brown algal polysaccharide sulfate, 0.004%-0.01% of an extract of root of kirilow rhodiola, 0.003%-0.005% of bamboo leaf flavone and 0.003%-0.005% of a fourstamen stephania root extract. The compound fulvate drug for silkworms has remarkable prevention and control effects to several main diseases such as viral disease, bacterial disease, fungal disease and the like of silkworms and has no toxic or side effect, drug resistance and drug residue; the requirement of simple silkworm breeding is met, and a new medication choice is provided for the comprehensive prevention and control of the diseases of the silkworms and the high yield and quality; a preparation process of the compound fulvate drug for silkworms is simple, relatively low in cost and suitable for scale production.

Description

technical field [0001] The invention relates to a compound silkworm medicine of fulvic acid salt, which belongs to the technical field of sericulture. Background technique [0002] During the growth and development of silkworms, multiple factors such as pathogenic microorganism infection, adverse physical and chemical stimuli, improper feeding techniques, and pest invasion often cause silkworm diseases, thereby threatening the survival, growth and development of silkworms, and reducing the The output and quality of silkworm cocoons have brought great risks and losses to silkworm farmers and even the entire sericulture industry. Therefore, effective prevention and control of silkworm diseases is the premise and basis for raising silkworms, harvesting cocoons, and obtaining higher economic benefits. [0003] Silkworm diseases are divided into infectious silkworm diseases and non-infectious silkworm diseases, and infectious silkworm diseases are the most serious diseases in si...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/899A61P31/04A61P31/10A61P31/12A61P37/04A61P1/14
Inventor 李宝才袁承李典张敉秦谊张惠芬任万云李顺
Owner KUNMING UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com